Search Results

Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension

November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).

Recor Medical’s Paradise uRDN System Launched in United States

November 14, 2023—Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd., have announced the first commercial uses of Recor’s Paradise ultrasound renal denervation (uRDN) system for the treatment of hypertension.

ReCor Medical’s Paradise Renal Denervation System Receives FDA Breakthrough Device Designation

December 10, 2020—ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices, announced that its catheter-based Paradise ultrasound renal denervation system has received FDA Breakthrough Device designation for the treatment of patients with uncontrolled hypertension who are not sufficiently responsive, or are intolerant, to antihypertensive medical therapy.

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

April 16, 2013—Accumetrics, Inc. (San Diego, CA) announced an expansion in the intended use for the company's CE Mark-approved VerifyNow P2Y12 test.

ReCor’s Paradise Ultrasound RDN System Shows BP-Lowering Effect at 24 Months in RADIANCE-HTN SOLO

November 4, 2021—Otsuka Medical Devices Co., Ltd., a fully owned subsidiary of Otsuka Holdings Co., Ltd., and its subsidiary ReCor Medical, Inc. announced the presentation of data from the RADIANCE-HTN SOLO trial demonstrating a durable blood pressure (BP)–lowering effect over 24 months for patients treated with Recor’s Paradise ultrasound renal denervation (RDN) system.

FDA Panel’s Vote Supports ReCor’s Paradise Renal Denervation Platform for Patients With Uncontrolled Hypertension

August 22, 2023—A panel convened to advise the US Food and Drug Administration on the safety and efficacy of renal denervation (RDN) for patients with uncontrolled hypertension has largely voted in support of ReCor Medical’s Paradise ultrasound RDN (uRDN) platform.

Shockwave Medical’s Intravascular Lithotripsy System Evaluated in Three Published Studies

June 28, 2021—Shockwave Medical, Inc. announced the publication of evaluations of the safety, efficacy, and mechanism of the benefit of the company’s intravascular lithotripsy (IVL) for the treatment of coronary and peripheral artery disease (PAD).

RADIANCE-HTN TRIO 6-Month Data Presented on Combined Effect of Medical Titration and RDN Treatment

November 4, 2021—The 6-month outcomes from the randomized RADIANCE-HTN TRIO trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.

Presentations Support Accumetrics' VerifyNow System for Platelet Reactivity Testing

March 12, 2013—Accumetrics, Inc. (San Diego, CA), maker of the VerifyNow system, announced the presentation of a series of data that solidifies the clinical utility of platelet reactivity testing.